[Zhixiang Jintai: Net profit in the third quarter was 310 million yuan, turning losses into profits year-on-year] On October 30, Zhixiang Jintai (688443.SH) announced that it achieved operating income of 778 million yuan in the first three quarters, a year-on-year increase of 274.75%; the net profit attributable to shareholders of the listed company was a loss of 6.3835 million yuan. In the third quarter, operating income was 625 million yuan, a year-on-year increase of 285.23%; net profit attributable to shareholders of listed companies was 310 million yuan, turning losses into profits year-on-year. The change in performance was mainly due to the company's recognition of GR1803 injection licensing revenue during the reporting period and the substantial increase in sales revenue from its first commercial product, Selizumab Injection, compared with the same period last year. Xiaocai's note: The company's Q3 net profit was 310 million, and Q2 net profit was -167 million. Based on this calculation, Q3 net profit turned from a loss to a profit.